Legislation signed this week by President Trump could pave the way for mesothelioma patients to access promising experimental treatments—even years before they are approved by the FDA. But not everyone thinks it is a good idea. The “Right to Try” legislation gives patients with terminal illnesses like malignant mesothelioma the right to receive new treatments they would not normally be able to get because they haven’t gone through the FDA’s three-phase testing requirement. Controversy Over New Legislation Although the legislation could make it easier for some patients to access potentially life-saving mesothelioma treatments, it is also not without controversy. Some argue it could even be dangerous. Typically, the FDA requires that all proposed mesothelioma therapies go through three-phases of studies … Continue reading Experimental Mesothelioma Drugs and the New Right-to-Try Law
A distinguished team of scientists are calling for a national mesothelioma registry they say could improve outcomes. If the registry collects and provides the right information, they say it could even help prevent future mesothelioma cases. Experts from the CDC, the National Institute for Occupational Safety and Health (NIOSH), and several top US cancer centers participated in a workshop on the topic. The Mesothelioma Applied Research Foundation convened the workshop. The group says existing tumor registries at some cancer centers are not as useful as a national mesothelioma registry. But coordinating a national registry will require government support. What is a Mesothelioma Registry? Malignant mesothelioma is a rare cancer which makes it hard to study. A national mesothelioma registry is … Continue reading Mesothelioma Registry Could Improve Outcomes, Prevent Future Cases
The first report using data from the newly-established Australian Mesothelioma Registry has been released, and the new is not good – especially for the country’s blue collar workers. According to the report from Safe Work Australia, a health and safety advocacy group for the country’s building industry, the Australian Mesothelioma Registry recorded 612 new cases of mesotheliomain 2011. The new national registry became operational in 2011 with a goal of recording and tracking all new mesothelioma cases. The purpose of the registry is to help spot trends, provide research data, etc. Six hundred and twelve new cases in 2011 equates to a rate of 2.7 mesothelioma cases per 100,000 people. However, Safe Work Australia cautions that the number is likely to … Continue reading Australian Registry Releases First Mesothelioma Report
To be given the news that you have cancer is probably the worst news a person can be given.
If I were faced with the decisions that Mr. O’Connor must have been following his prognosis concerning the mesothelioma deteriorating the inside of his body, I can only imagine that I would follow a similar pathway as Rhio.
“A Brighter Future”
A Texas man who spent his career painting buildings was awarded $11 million after he claimed to have developed mesothelioma from asbestos-containing painting products. Vernon Walker, 67, of Dallas spent years working daily with contaminated products such as texturing paints, block fillers and drywall compounds, some of which were banned by the Consumer Products Safety Commission in the 1970’s because of their asbestos. Forty percent of the $11 settlement is to come from asbestos mining company Union Carbide and the rest from various paint product manufacturers. Union Carbide took another recent hit in court from a former employee, who won his $3 million suit against the company and two others he blamed for his mesothelioma. Oscar Torres’ suit alleged that workers at … Continue reading Mesothelioma Lawsuits Continue Throughout Country
Italian researchers say a curcumin supplement containing a compound found in black pepper slowed the growth of mesothelioma tumors in mice. The commercially available supplement is called Curcumin-C3complex/Bioperine. This is the first time this formulation has been studied for malignant mesothelioma. Lab-grown human mesothelioma cells stopped growing when scientists treated them with the curcumin supplement. The treatment did the same in live mice. The researchers suggest that the curcumin supplement may work synergistically with standard treatments. What is in Curcumin-C3complex/Bioperine? Curcumin is the most bioactive compound in turmeric. Turmeric is the spice that gives curry its bright yellow color. Several scientific studies suggest that curcumin and other curcuminoid compounds in turmeric have powerful health benefits. These compounds are anti-inflammatory and … Continue reading Curcumin Supplement Delays Mesothelioma Tumor Growth in Mice
A new report contains some disappointing news for former asbestos workers: The risk for mesothelioma does not go down when asbestos exposure stops. A team of US and Italian researchers reached that conclusion after combing the medical literature for studies on the risk for mesothelioma. Although the risk for several other cancers declines when the person is no longer in contact with the carcinogen, the study shows this does not apply to asbestos cancer. Asbestos Increases Mesothelioma Risk Asbestos is the primary cause of mesothelioma. It is a naturally-occurring mineral that is resistant to corrosion, does not burn, and makes an excellent insulator. Malignant mesothelioma was virtually unheard of until people started mining and using asbestos in industry. Since then, … Continue reading Risk for Mesothelioma Does Not Decline After Asbestos Exposure Stops
A Dutch company has recruited the first patients into a pivotal mesothelioma clinical trial of autologous dendritic cells. Dendritic cells are immune system cells that work as messengers. They help tell T cells to attack cancers like malignant mesothelioma. The new mesothelioma clinical trial will test using the patient’s own dendritic cells (autologous cells) as a way to keep cancer from coming back after mesothelioma treatment. Expanding Mesothelioma Treatment Options There is only one approved treatment for malignant pleural mesothelioma. This “standard of care” treatment is chemotherapy with Alimta (pemetrexed) and cisplatin. Although most mesothelioma patients receive this treatment, very few live longer than a year after diagnosis. A Netherlands-based company called Amphera is trying to change those odds. Its … Continue reading New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy